Search Result for : Indian Pharmaceutical Exports

The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...

The Dollar Business Bureau Indian Pharma exports to the US may increase in 2017-18 despite pricing pressure and stiff competition. A report released by Care Ratings said that $50 billion worth of drugs are expected to become 'off-patent' in the current year giving hope to the Indian Pharma export market. "The pharma export volumes from India to US, however, are expected to rise. This will be backed by about $55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," ...

Sharath Chowdary Shantha Biotechnics has started commercial production of its new manufacturing unit in Muppireddipalli Special Economic Zone (SEZ) near Hyderabad. With an investment of over Rs.250 crore, the new facility has been built to produce and export vaccines to the United Nations Children's Emergency Fund (UNICEF) and other international markets. The company is completely owned by Sanofi Pasteur, the vaccines division of French pharma company Sanofi Group. Another manufacturing facility is also being set up in Hyderabad with an investment of Rs.450 crore for the production of Insuman, human insulin, used in the treatment of diabetes. This plant is expected to commence its operations next year, Varaprasad Reddy, Chairman of Shantha Biotechnics told The Dollar Business.  He said, “The two facilities are ...

The Dollar Business Bureau The growth of Indian pharmaceutical exports is likely to come down to 10-12% y-o-y during the next five years, when compared to the growth of 19% in the past ten years, as per CRISIL Research. Due to the decreasing value of off-patent drugs and increasing pressure on prices, the exports of generics have less impact on the growth of the pharma industry, it said. According to CRISIL Research, Indian pharma companies must enhance their investments in new molecules for sustainable growth till 2020 and beyond. The domestic companies shall also prepare a roadmap related to the growth of lower generics. In the last 10 years, process chemistry skills have helped pharma companies to clone off-patent drugs by tweaking ...

 The Dollar Business Bureau Aurobindo Pharma, a Hyderabad-based company, has announced that it has finally received approval to manufacture and market Oxymorphone Hydrochloride and Famotidine tablets from the United States Food and Drug Administration (USFDA). The approved Abbreviated New Drug Application (ANDA) is bio and therapeutic equivalent to listed drug under Reference Listed Drug (RLD). Manufactured by Endo Pharmaceuticals, Inc., Oxymorphone Hydrochloride is a pain relief drug for moderate to acute pain, wherever the prescription of Opioid is appropriate. As approved by ANDA, dosages must be 5mg and 10mg. According to IMS Health, the product has a market size of $55.5 million for a period of 12-months, ending February 2016. While, Famotidine tablets (ANDA approved dosages for this drug is ...